Other common side effects include transient headache, fatigue or dizziness, and injection-site reactions, but significant hypoglycemia is rare when GLP-1 RAs are used alone (hypoglycemia generally only occurs if combined with insulin or sulfonylureas) (15)
And for many patients, it dramatically reduces obesity-related conditions like type 2 diabetes, high blood pressure and heart disease. Looking Ahead: The Future of Weight Management The emergence of non-injectable GLP-1 medications signals a future where weight management is more personalized, flexible and patient-centered than ever before
As we follow long-term outcomes of current therapies with new medications coming to market, it will be crucial to continue to evaluate lipid-specific outcomes that play a role in the overall cardiovascular benefits of GLP-1RA and other highly effective anti-obesity medications
Maintain a healthy weight, as excess weight increases intra-abdominal pressure
10.1152/ajpendo.00665.2010 59